ARCHIVES

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

This article is from The Cancer Letter archive.

Vol. 31 No. 22 | June 3, 2005

Download PDF Visit The Full Archive

Related Articles

New Chemoprevention Program Will Get “Whatever Money It Need;” Clinical Trials In New Division

July 25, 1980

Senate Increases NIH Funding for 2013, Rejects President’s $200+ Million Increase for Program Evaluation Activities

June 22, 2012

Columbia Formally Names As 21st Comprehensive Center

March 9, 1979

Guideline Revisions or Outstanding Investigator Grant Still Controversial

December 9, 1983

Civin Moves From Hopkins To Maryland To Direct Stem Cell Medicine Center

January 9, 2009

Clinical Trials: Phase I Trial of Karenitecin Begins, BioNumerik Says

March 5, 1999